Ingrid Swanson Pultz
Chief Technology Officer at Mopac
Ingrid Swanson Pultz is CTO and Translational Advisor at Mopac Biologics, and also serves as Chief Technology Officer at Mopac and as a Protein Design Researcher at the University of Washington.
Takeda buys Seattle startup PvP Biologics for up to $330M, will advance TAK-062 into Phase 2
Japanese pharmaceutical Takeda acquired Seattle biotech PvP Biologics for up to $330 million in late February, taking over its TAK-062 (Kuma062) program and all clinical and manufacturing activities while laying off PvP staff. Takeda plans to run phase 2 trials of the enzyme-based celiac disease treatment that PvP developed after earlier funding of $35 million supported phase 1 work.
Organizations
-
Mopac Chief Technology Officer · current
-
Mopac Biologics CTO and Translational Advisor · current
-
University of Washington Protein Design Researcher · current
